May 2, 2022 -- BeiGene has broken ground on a new manufacturing and clinical R&D center to be built at the Princeton West Innovation Campus located in Hopewell, NJ. The planned 400,000-sq-ft facility will be constructed to support the manufacturing of various biologics produced by BeiGene.
The facility will be built with the capacity to contain up to 16,000 liters of biologics formula to be used in the manufacturing process.
The new site will also enable continued research and development for the company's cancer treatments, alongside the facilities required to manufacture these therapies. The property, acquired from the Lincoln Equities Group in November 2021, also includes more than 1 million sq ft of real estate available for further development and expansion.
The opening of this facility will encourage economic growth and employment opportunities for residents in the Hopewell area, while also facilitating the operation of manufacturing processes related to novel biologics and cancer therapies.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
